Adalimumab – USA

Adalimumab – USA

Decision on IPR: Nov 02, 2018

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Status
IPR2017-02105
09/14/2017
04/03/2018
Sandoz Inc.
9,090,689
AbbVie
Terminated – Settled
IPR2017-02106
09/14/2017
04/03/2018
Sandoz Inc.
9,067,992
AbbVie
Terminated – Settled
US 9,090,689 (AbbVie Biotechnology, Ltd; Exp: Jul 18, 2023)
1. A method of administering adalimumab for treatment of moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.
7. A method of preparing adalimumab for treating moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and providing said adalimumab for treatment, wherein said treatment comprises subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.
US 9,067,992 (AbbVie Biotechnology, Ltd; Exp: Jul 18, 2023)
1. A method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has .gtoreq.3 swollen and .gtoreq.3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved